Proton therapy review
This article was originally published in The Gray Sheet
Executive Summary
Agency for Healthcare Research & Quality is seeking comments through Aug. 27 on a draft "technical brief" assessing particle beam radiotherapy. The emerging technology, an alternative to photon beam radiotherapy for cancer treatment, is available at six U.S. centers (about 30 worldwide). The potential advantage of particle, most commonly proton, beams is more precise delivery of treatment that can spare healthy tissues. Because constructing a photon therapy center can cost over $100 million, AHRQ says that the advantages of particle beam therapy versus alternative interventions need to be proven in controlled trials, along with economic evaluations before the technology gets widely adopted. Particle beam therapy developers include IBA Solutions, Optivus Proton Therapy, Hitachi, Siemens and Varian Medical Systems ("The Gray Sheet" Jan. 8, 2007, p. 9)
You may also be interested in...
Varian Medical Spins Into Proton Radiotherapy With $30 Mil. Purchase
Varian Medical Systems will bulk up its cancer treatment portfolio with a $30 million acquisition of Germany-based Accel, announced Jan. 4
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.